Advanced search
Publication Cover
Acta Cardiologica Volume 70, 2015 - Issue 4
Submit an article Journal homepage
42
Views
12
CrossRef citations to date
0
Altmetric
Articles

Procalcitonin: a marker of heart failure

Alper CanbayDept. of Cardiology, Medicana International Ankara Hospital, Ankara, Turkey
, MD,
Ozlem Ozcan CelebiDept. of Cardiology, Medicana International Ankara Hospital, Ankara, TurkeyCorrespondence[email protected]
, MD,
Savas CelebiDept. of Cardiology, TOBB ETU Hospital, Ankara, Turkey
, MD,
Sinan AydogduDept. of Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey.
, MD &
Erdem DikerDept. of Cardiology, Medicana International Ankara Hospital, Ankara, Turkey
, MD
Pages 473-478 | Published online: 23 May 2017

References

  • Krum H, TeerlinkJR. Medical therapy for chronic heart failure. Lancet 2011; 378:713–21.
  • Sato Y, Fujiwara H, Takatsu Y. Biochemical markers in heart failure. J Cardiol 2012; 59:1–7.
  • Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int JCardiol 2009; 132: 303–11.
  • lqbal N, Alim KS, Aramin H, lqbal F, Green E, Higginbotham E, Maisel AS. Novel biomarkers for heart failure. Expert Rev Cardiovasc Ther 2013; 11:1155–69.
  • Maisel AS, Choudhary R. Biomarkers in acute heart failure--state of the art. Nat Rev Cardiol 2012; 9: 478–90.
  • Naffaa M, Makhoul BF, Tobia A, Jarous M, Kaplan M, Aronson D, Saliba W, Azzam ZS. Brain natriuretic peptide at discharge as a predictor of 6-month mortality in acute decompensated heart failure. Am J Emerg Med 2014; 32: 44–9.
  • Simon L, Gauvin F, Amre DK, Saint-Louis P. Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206–17.
  • Sponholz C, Sakr Y, Reinhart K, Brunkhorst F. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006; 10: R145.
  • Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chem other 2012; 67: 2560–9.
  • Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med 2013; 28: 285–291.
  • Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011; 52 Suppl 4:S346–50.
  • Adib-Conquy M, Monchi M, Goulenok C, Laurent I, Thuong M, Cavaillon JM, Adrie C. Increased plasma levels of soluble triggering receptor expressed on myeloid cells 1 and procalcitonin after cardiac surgery and cardiac arrest without infection. Shock 2007; 28: 406–10.
  • Dörge H, Schondube FA, Dörge P. Seipelt R, Voss M, Messmer BJ. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. Thorac Cardiovasc Surg 2003; 51:322–6.
  • Wang W, Zhang X, Ge N, Liu J, Yuan H, Zhang P. Liu W, Wen D. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. Crit Care 2014; 18: R4.
  • Miller WL, Hartman KA, Hodge DO, Hartman S, Struck J, Morgenthaler NG, Bergmann A, Jaffe AS. Response of novel biomarkers to BNP infusion in patients with decompensated heart failure: a multimarker paradigm. J Cardiovasc Transl Res 2009; 2: 526–35.
  • The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Little, Brown & Co., Boston, 1994: 253–6.
  • Maruna P. Nedelnikova R, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res 2000; 49: 557–61.
  • Nijsten M, Olinga P. The TH, de Vries EG, Koops HS, Groothuis GM, Limburg PC, ten Duis HJ, Moshage H, Hoekstra HJ, Bijzet J, Zwaveling JH. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28:458–61.
  • Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, Jöger L, Reinhart K. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134:49–55.
  • Remskar M, Horvat M, Hojker S, Noc M. Procalcitonin in patients with acute myocardial infarction. Wien Klin Wochenschr 2002; 114: 205–10.
  • Sandek A, Springer J, Habedank D, Brunkhorst F, Anker SD. Procalcitonin-guided antibiotic treatment in heart failure. Lancet 2004; 363: 1555–6.
  • Panagopoulou V. Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G, Pyrga kis V, Cleman MW. NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem 2013; 13: 82–94.
  • Aouifi A, Piriou V. Bastien O, Blanc P. Bouvier H, Evans R, Célard M, Vandenesch F, Rousson R, LehotJJ. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 2000; 28:3171–6.
  • Koszegi T. I mmunoluminometric detection of human procalcitonin. J Biochem Biophys Methods 2002; 53: 157–64.
  • Goode KM, Nicholls R, Pellicori P. Clark AL, Cleland JG. The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature. Clin Chem Lab Med 2014; 52: 911–8.
  • Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48: 2325–9.
  • Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003; 29: 579–83.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.